4 It was reported that the CA125 levels in peritoneal eﬄuent were higher in patients treated with low-GDP solution than in those treated with conventional solution [28]. Do et al. observed diﬀerences in dialysate-VEGF/CA125 levels between the low- and high-GDP groups during the initial 12 months, but did not observe any diﬀerence in the unadjusted VEGF concentration [6]. From our data, patients with high transport rate displayed higher HGF, VEGF, and IL-6 levels. While, eﬄuent HGF/CA125, and VEGF/CA125 levels were not signiﬁcantly diﬀerent between patients with high transport rate and others. Furthermore, IL-6/CA125 eﬄuent level did not show a stronger relation with D/P creatinine than unadjusted IL-6. Breborowicz reported that CA 125 does not a good index of the number of mesothelial cells or their functional properties, because the amount of CA125 released from mesothelial cells is not only depend on the number of cells, but also on their properties, age of cell donor, and environmental factors [29]. We consider that the eﬄuent concentrations of growth factors should be measured relative to mesothelial mass integrity and that the CA125 eﬄuent level may not be a suitable surrogate marker for this purpose. Our study has certain limitation. The small number of the patients in the high transport group and shorter duration of the PD in this group may aﬀect the results. In conclusion, increase in the eﬄuent HGF levels as a compensatory mecha- nism is a marker of peritoneal deterioration, but controversy remains regarding the adjustment of markers for CA125. Conﬂict of Interests The authors declare that there is no conﬂict of interests. References [1] L. S. Aroeira, A. Aguilera, J. A. Sa´nchez-Tomero et al., “Epithe- lial to mesenchymal transition and peritoneal membrane fail- ure in peritoneal dialysis patients: pathologic signiﬁcance and potential therapeutic interventions,” Journal of the American Society of Nephrology, vol. 18, no. 7, pp. 2004–2013, 2007. [2] M. Ya´n˜ez-Mo´ , E. Lara-Pezzi, R. Selgas et al., “Peritoneal dial- ysis and epithelial-to-mesenchymal transition of mesothelial cells,” The New England Journal of Medicine, vol. 348, no. 5, pp. 403–413, 2003. [3] O. Devuyst, P. J. Margetts, and N. Topley, “The pathophysi- ology of the peritoneal membrane,” Journal of the American Society of Nephrology, vol. 21, no. 7, pp. 1077–1085, 2010. [4] M. A. Yu, K. S. Shin, J. H. Kim et al., “HGF and BMP-7 ameliorate high glucose-induced epithelial-to-mesenchymal transition of peritoneal mesothelium,” Journal of the American Society of Nephrology, vol. 20, no. 3, pp. 567–581, 2009. [5] J. Loureiro, M. Schilte, A. Aguilera et al., “BMP-7 blocks mes- enchymal conversion of mesothelial cells and prevents peri- toneal damage induced by dialysis ﬂuid exposure,” Nephrology Dialysis Transplantation, vol. 25, no. 4, pp. 1098–1108, 2010. [6] J. Y. Do, Y. L. Kim, J. W. Park et al., “The association between the vascular endothelial growth factor-to-cancer antigen 125 ratio in peritoneal dialysis eﬄuent and the epithelial-to- mesenchymal transition in continuous ambulatory peritoneal International Journal of Nephrology dialysis,” Peritoneal Dialysis International, vol. 28, no. 3, sup- plement, pp. S101–S106, 2008. [7] R. T. Krediet, “Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis,” Peritoneal Dialysis International, vol. 21, no. 6, pp. 560–567, 2001. [8] I. Nishizono, S. Iida, N. Suzuki et al., “Rapid and sensi- tive chemiluminescent enzyme immunoassay for measuring tumor markers,” Clinical Chemistry, vol. 37, no. 9, pp. 1639– 1644, 1991. [9] P. Kenemans, G. J. Van Kamp, P. Oehr, and R. A. Verstraeten, “Heterologous double determinant immunoradiometric assay CA 125 II. Reliable second-generation immunoassay for determining CA 125 in serum,” Clinical Chemistry, vol. 39, no. 12, pp. 2509–2513, 1993. [10] S. J. Davies, J. Bryan, L. Phillips, and G. I. Russell, “Longitu- dinal changes in peritoneal kinetics: the eﬀects of peritoneal dialysis and peritonitis,” Nephrology Dialysis Transplantation, vol. 11, no. 3, pp. 498–506, 1996. [11] R. Yamamoto, M. Nakayama, T. Hasegawa et al., “High- transport membrane is a risk factor for encapsulating peri- toneal sclerosis developing after long-term continuous ambu- latory peritoneal dialysis treatment,” Advances in peritoneal dialysis. Conference on Peritoneal Dialysis, vol. 18, pp. 131–134, 2002. [12] M. Nakayama, H. Yamamoto, M. Ikeda et al., “Risk factors and preventive measures for encapsulating peritoneal sclerosis– Jikei experience 2002,” Advances in Peritoneal Dialysis, vol. 18, pp. 144–148, 2002. [13] Y. Kawaguchi, A. Saito, H. Kawanishi et al., “Recommenda- tions on the management of encapsulating peritoneal sclerosis in Japan, 2005: diagnosis, predictive markers, treatment, and preventive measures,” Peritoneal Dialysis International, vol. 25, no. 4, supplement, pp. S83–S95, 2005. [14] D. N. Churchill, K. E. Thorpe, K. D. Nolph, P. R. Keshaviah, D. G. Oreopoulos, and D. Page´, “Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients,” Journal of the American Society of Nephrology, vol. 9, no. 7, pp. 1285– 1292, 1998. [15] H. Nakamoto, H. Suzuki, H. Imai et al., “Hypoproteinemia in patients with diabetes undergoing continuous ambulatory peritoneal dialysis is attributable to high permeability of peri- toneal membrane,” Peritoneal Dialysis International, vol. 23, supplement 2, pp. S72–S78, 2003. [16] Y. L. Kim, “Update on mechanisms of ultraﬁltration failure,” Peritoneal Dialysis International, vol. 29, no. 2, supplement, pp. S123–S127, 2009. [17] G. Del Peso, J. A. Jime´nez-Heﬀernan, M. A. Bajo et al., “Epithelial-to-mesenchymal transition of mesothelial cells is an early event during peritoneal dialysis and is associated with high peritoneal transport,” Kidney International, vol. 73, no. 108, supplement, pp. S26–S33, 2008. [18] L. S. Aroeira, A. Aguilera, R. Selgas et al., “Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: role of vascular endothelial growth factor,” American Journal of Kidney Diseases, vol. 46, no. 5, pp. 938–948, 2005. [19] L. S. Aroeira, E. Lara-Pezzi, J. Loureiro et al., “Cyclooxygenase- 2 mediates dialysate-Lnduced alterations of the peritoneal membrane,” Journal of the American Society of Nephrology, vol. 20, no. 3, pp. 582–592, 2009.